Q J Med 2000; 93:497±499 Editorial QJM

Warfarin for ?

In 1983, Poser et al.1 established their criteria for Seventeen of them met Poser's criteria for definite the diagnosis of multiple sclerosis MS). In the same or probable MS. The most frequent manifestations year, Hughes2 described the association between were transverse myelitis and , which thrombosis, abortion, cerebral disease and were seen, alone or in combination, in 12 patients. anticoagulant. These reports have eventually Twenty-two of the 23 MRI studies performed were become connected. Today, almost 20 years later, abnormal. After being re-evaluated by a radiologist there are enough data to consider antiphospholipid unaware of the previous reading, 12 studies were syndrome APS), or Hughes' syndrome, as a major labelled as diagnostic or compatible with MS, differential in the diagnosis of definite or probable whilst in the remaining 11, MS was not the leading MS according to Poser's criteria. diagnosis, but could not be excluded. aPL were Arterial thrombosis is a major feature of Hughes' positive in all patients it was an inclusion criteria); syndrome, vessels being 14 had IgG and/or IgM medium/high titres and/or among the most frequently affected.3 The resulting LA. Twelve patients had clinical features suggesting clinical event is generally a stroke. However, more the presence of APS or systemic autoimmune complex manifestations may include multifocal disease, such as Raynaud's, livedo reticularis, sensory, motor or cognitive dysfunction, optic miscarriages, rash, arthritis or sicca syndrome. neuritis, transverse myelitis and a combination of Also in 1998, Karussis et al.6 published a the last two Devic's syndrome). Different areas are neurologists' perspective on this issue. They identi- often affected during the progression of the disease. fied a cohort of 100 patients with MS according to Magnetic resonance imaging MRI) studies in these Poser's criteria but with unusual features, such as patients frequently show multiple T2 hyperintense headaches, progressive myelopathy and absence of brain lesions. This combinationÐrelapsing/remit- oligoclonal bands in the cerebrospinal fluid CSF). ting multifocal neurological symptoms plus the MRI Twenty of these patients were found to have findingsÐmay closely resemble MS. persistently positive aCL of the IgG isotype. In recent years, the number of patients in the Nineteen had MRI findings typical of MS, including medical literature diagnosed with MS and later T2 hyperintense lesions in the white matter, without shown to have antiphospholipid antibodies aPL) enhancing after gadolinium injection in any of the has grown substantially. In 1994, Scott et al.4 13 patients with myelopathy. Spinal cord involve- reported four patients presenting with multiple ment was also frequent in this series, 15 patients). neurological manifestations, including vertigo, Optic neuritis and cerebellar lesions were the two aphasia, unilateral visual loss, diplopia or hemipar- other main forms of presentation. The clinical esis, in different combinations over several years, course of this cohort was different from `classical' with variable degrees of recovery after the episodes. MS, including a slower rate of progression, a higher All had white-matter lesions and all had received incidence of headaches and a frequent absence of the clinical label of MS. Anticardiolipin antibodies oligoclonal bands. aCL) of the IgG isotype were positive at medium to Recently, we have reported on a group of 27 high levels in the four patients, and lupus antic- patients who were initially diagnosed by a neurol- oagulant LA) was also found in three of them. In ogist as having MS, but were referred to our Unit addition, all but one patient had previous clinical due to atypical features.7 All of them were subse- manifestations suggestive of APS, such as venous quently found to have aCL IgG and/or IgM in thrombosis, recurrent miscarriages and thrombocy- medium/high titres and/or LA. Assuming the topenia. ischaemic nature of their neurological symptoms, In 1998, Ijdo et al.5 published a series of 23 all of them fulfilled the classification criteria for patients with the clinical suspicion of MS. APS,8 16 primary and 11 secondary to systemic

ß Association of Physicians 2000 498 Editorial lupus erythematosus. Transverse myelitis was the not necessarily exclude APS, since a small number presenting feature in 22% of patients of this series. of patients in the above series exhibited this Other manifestations included optic neuritis with feature.4±6 More specific neuroimaging techniques myelopathy in three cases), vertigo, , aphasia, are being developed, and a recent study by Rovaris focal weakness and numbness. MRI studies were et al.11 suggested that magnetization transfer imag- abnormal in 23 patients. Blinded comparison of ing combined with standard MRI can detect these MRIs with those from a group of 25 controls microscopic brain tissue damage and discriminate with definite MS without aPL could not distinguish between patients with MS and those with APS. which patients belonged in which group. However, in this study the images obtained in a Some `negative' studies that appear to refute the group of SLE patients with neurological symptoms association between APS and MS-like clinical were indistinguishable from those of MS patients. features have also been published. Rombos et al.9 The authors did not report the nature of the compared the levels of IgG and IgM aCL in two neurological symptoms in this group with SLE, nor groups of patients with MS n=42) and myasthenia did they comment on the presence of aPL in them. gravis n=21) and 210 healthy individuals. They did However, positivity for aPL is very high in SLE not find any difference in the mean titres of aCL patients with white-matter lesions,12 so the diag- among the three populations. Tourbah et al.10 nosis of secondary APS can not be excluded in evaluated the presence of manifestations suggestive Rovari's SLE group. Accordingly, no single test of in 161 patients with definite discriminates between ischaemic secondary to MS. Eight of the patients with a prolonged follow-up APS) and inflammatory secondary to MS) white- had aCL, but no specific clinical features were matter lesions. found in this subgroup. However, what both studies Recommendations about treatment can only be confirmed is that aPL are found in only a minority of based on the limited evidence of the above series, patients with MS. In keeping with this, the group of and can not therefore be considered absolute. Karussis found aPL in only 5.7% of patients from Obviously, in patients who are consistently positive their cohort with classical MS.6 for aPL aCL IgG and/or IgM at medium to high titres To what degree do these antibodies represent an and/or LA), anticoagulation can be considered. The alternative diagnosis rather than an incidental presence of clinical features such as migraine, finding? The answer to this question is not thrombocytopenia, previous thrombosis, livedo straightforward, since no gold standard can differ- reticularis, recurrent early miscarriages or an entiate MS from Hughes' syndrome with cerebral unexplained fetal loss, or a concomitant diagnosis involvement. However, some clues suggest the of SLE or SjoÈgren's syndrome, make the possibility existence of two different conditions. Migraine is a of a thrombotic cause for the neurological manifes- frequent complaint in the aPL-positive group of tations more likely. In this group, as in other APS patients,6,7 whilst the presence of oligoclonal bands patients with neurological features such as stroke, in the CSF is found much more rarely than in anticoagulation can stop the progression of the classical MS.5,6 Both facts point to vascular rather symptoms and substantially improve the prognosis than inflammatory pathogenetic mechanisms. of the disease. Other clinical manifestations in aPL-positive G. Ruiz-Irastorza patients include livedo reticularis, sicca syndrome, M.A. Khamashta Raynaud's, miscarriages5 or even the presence of Lupus Research Unit overt SLE.7 However, the strongest evidence for the The Rayne Institute presence of two different diseases is the striking St Thomas' Hospital response to oral anticoagulation seen in the London different groups of patients with aPL: The neurolog- ical symptoms did not recur, respectively, in 3/3,4 9/95 and 8/12 patients without SLE7 treated with warfarin. Six out of nine patients with SLE in our series also responded to anticoagulation.7 All these References facts suggest that a proportion of patients with APS is actually mislabelled as having MS. Accordingly, 1. Poser CM, Paty CW, Scheinberg L, McDonald WJ, Davis FA, both IgG and IgM aCL and LA should be routinely Ebers GC, Johnson KD, Sibley W, Silberberg DH. New diagnostic criteria for multiple sclerosis: Guidelines for included in the evaluation of any patient presenting research protocols. Ann Neurol 1983; 13:227±31. with symptoms suggesting MS. 2. Hughes GRV. Thrombosis, abortion, cerebral disease and The absence of oligoclonal bands in the CSF lupus anticoagulant. Br Med J 1983; 287:1088±9. should be regarded as evidence against the diag- 3. Hughes GRV. The antiphospholipid syndrome: ten years on. nosis of classical MS,6 although its presence does Lancet 1993; 342:341±4. Editorial 499

4. Scott TF, Hess D, Brillman J. Antiphospholipid antibody antiphospholipid syndrome. Arthritis Rheum 1999; syndrome mimicking multiple sclerosis clinically and by 42:1309±11. magnetic resonance imaging. Arch Intern Med 1994; 9. Rombus A, Evangelopoulou-Katsiri E, Leventakou A, 154:917±20. Voumvourakis K, Triantafyllou N, Papageorgiou C. Serum 5. IJdo JW, Conti-Kelly AM, Greco P, Abedi M, Amos M, IgG and IgM anticardiolipin antibodies in neurological Provenzale JM, Greco TP. Anti-phospholipid antibodies in diseases. Acta Neurol Scand 1990; 81:243±5. patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus 1999; 8:109±15. 10. Tourbah A, Clapin A, Gout O, Fontaine B, Liblau R, Batteux F, StieÂvenart JL, Weill B, Lubetzki C, Lyon-Caen O. Systemic 6. Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup autoimmune features and multiple sclerosis. A 5-year of multiple sclerosis patients with anticardiolipin antibodies follow-up study. Arch Neurol 1998; 55:517±21. and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol 1998; 44:629±34. 11. Rovaris M, Viti B, Ciboddo G, Gerevini S, Capra R, Iannucci G, Comi G, Filippi M. Brain involvement in systemic 7. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of immune mediated diseases: magnetic resonance and Hughes' antiphospholipid) syndrome be distinguished from magnetisation transfer imaging study. J Neurol Neurosurg multiple sclerosis? Analysis of 27 patients and review of the Psychiatry 2000; 68:170±7. literature. Medicine #Baltimore) 2000; 79:57±68. 12. Haculla E, Michon-Pasturel U, Leys D, Pruvo JP, Queyrel V, 8. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Masy E, Arvieux J, Caron C, Brevet-Coupe F, Hatron PY, Piette JC, Brey R, Derksen R, Harris EN, Hughes GRV, Devulder B. Cerebral magnetic resonance imaging in Tripplet DA, Khamashta MA. International consensus patients with or without antiphospholipid antibodies. statement on preliminary classification criteria for definite Lupus 1998; 7:124±31.